Inhibition of Mantle Cell Lymphomas by the beta 2-Adrenergic Agonist, Levalbuterol, in Hollow Fiber Assay in Mice

This study follows from the novel findings in our previous publication that {beta}2-adrenergic receptor ({beta}2AR) agonists show gene-expression signatures that are consistent with glucocorticoid receptor (GR) agonists. These observations were made with analytical software associated with the Harvard/MIT genomic database, CLUE. This formed a hypothesis that {beta}2AR agonists would share the anti-inflammatory activity of GR agonists and their ability to induce apoptosis in tumors of lymphatic lineage. Our lead {beta}2AR agonist from our previous study, levalbuterol, was tested for inhibitory activity upon 3 non-Hodgkin human cell lines, two of which were Mantle Cell carcinomas, JEKO-1 and MINO, and against SU-DHL-1, in mice: Species: Mus musculus; Strain: NMRI nude (Crl:NMRI-Foxn1nu), Sex: Females. The drug was supplied ad libitum in the drinking water at concentrations of 8 {micro}g/ml and16 {micro}g/ml over a period of 14 days. Statistically significant inhibition of lymphoma proliferation was observed at the higher concentration of levalbuterol. The data for the 3 cultures were combined to increase the power of the analysis. The average inhibition was 55 %, p <0.0001, consistent with the hypothesis that the {beta}2AR agonist shared the apoptotic activity of the GR agonists with which it had similar gene-expression activity.